Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Share-based Compensation (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Share-based Compensation for 6 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 21.08% year-over-year to $5.5 million, compared with a TTM value of $24.6 million through Dec 2025, down 8.43%, and an annual FY2025 reading of $24.6 million, down 8.43% over the prior year.
  • Share-based Compensation was $5.5 million for Q4 2025 at Cytek Biosciences, down from $5.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $7.2 million in Q2 2024 and bottomed at $456000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $4.9 million, with a median of $5.6 million recorded in 2025.
  • The sharpest move saw Share-based Compensation surged 2184.13% in 2021, then dropped 21.08% in 2025.
  • Year by year, Share-based Compensation stood at $3.0 million in 2021, then soared by 48.44% to $4.5 million in 2022, then grew by 26.97% to $5.7 million in 2023, then increased by 23.53% to $7.0 million in 2024, then decreased by 21.08% to $5.5 million in 2025.
  • Business Quant data shows Share-based Compensation for CTKB at $5.5 million in Q4 2025, $5.6 million in Q3 2025, and $6.8 million in Q2 2025.